The efficacy results of several trials have been uneven in the metastatic scenario, despite the FDA’s approval of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Here, CDK4 is linked to breast cancer.